1. T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses.
- Author
-
Kristian, Taipale, Ilkka, Liikanen, Juuso, Juhila, Aila, Karioja-Kallio, Minna, Oksanen, Riku, Turkki, Nina, Linder, Johan, Lundin, Ari, Ristimäki, Anna, Kanerva, Anniina, Koski, Timo, Joensuu, Markus, Vähä-Koskela, and Akseli, Hemminki
- Subjects
- *
ADENOVIRUSES , *IMMUNE response , *MUCINOUS adenocarcinoma , *BLOOD viscosity , *TUMORS , *PATIENTS - Abstract
The quality of the antitumor immune response is decisive when developing new immunotherapies for cancer. Oncolytic adenoviruses cause a potent immunogenic stimulus and arming them with costimulatory molecules reshapes the immune response further. We evaluated peripheral blood T-cell subsets of 50 patients with refractory solid tumors undergoing treatment with oncolytic adenovirus. These data were compared to changes in antiviral and antitumor T cells, treatment efficacy, overall survival, and T-cell subsets in pre- and post-treatment tumor biopsies. Treatment caused a significant (P < 0.0001) shift in T-cell subsets in blood, characterized by a proportional increase of CD8+ cells, and decrease of CD4+ cells. Concomitant treatment with cyclophosphamide and temozolomide resulted in less CD4+ decrease (P = 0.041) than cyclophosphamide only. Interestingly, we saw a correlation between T-cell changes in peripheral blood and the tumor site. This correlation was positive for CD8+ and inverse for CD4+ cells. These findings give insight to the interconnections between peripheral blood and tumor-infiltrating lymphocyte (TIL) populations regarding oncolytic virotherapy. In particular, our data suggest that induction of T-cell response is not sufficient for clinical response in the context of immunosuppressive tumors, and that peripheral blood T cells have a complicated and potentially misleading relationship with TILs. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF